BMS Sighs In Relief As Opdivo Returns To Sales Growth

Bristol Myers Squibb Company was able to highlight some key positives for its immuno-oncology business in releasing its second quarter sales and earnings on 28 July, chiefly that its PD-1 checkpoint inhibitor Opdivo (nivolumab) has returned to growth after a pandemic-related decline and that prospects look good for adding new checkpoint inhibitor classes. But there are negatives as well – in the form of the failure of Opdivo plus Yervoy (ipilimumab) in gastric cancer and manufacturing issues for its CAR-T products

Opdivo posted 16% year-over-year sales growth, including 13% growth in US sales, as BMSunveiled a solid Q2 2021 earnings report on 28 July, including substantial growth for Eliquis